{
    "Case ID": "080457",
    "Different Crime": [
        {
            "Crime Name": "Patent Infringement",
            "Crime Type": "Economic_Crimes_or_Fraud-related_Offenses",
            "legal_basis": [
                "Canadian Patent Law",
                "Canadian Patent Act"
            ],
            "patent_validity": [
                "utility",
                "non-obviousness",
                "sufficient disclosure"
            ],
            "expert_testimony": [
                "considered"
            ],
            "decision_outcome": [
                "Novartis's patent was upheld for compound claims"
            ],
            "procedural_fairness": [
                "Federal Court analyzed Teva's allegations"
            ],
            "applicable_statute": [
                "utility",
                "obviousness",
                "sufficiency"
            ],
            "technical_details": [
                "compound claims were valid",
                "use claims lacked demonstrated utility"
            ],
            "standard_of_review": [
                "significant inventive steps were involved"
            ],
            "cause_of_action": [
                "Teva sought to market a generic version of Novartis's patented drug EXJADE"
            ]
        }
    ]
}